

OPHENYL)-1-PIPERAZINYL) BUTOXY)-3,4-DIHYDROCARBOSTYRIL"/BI)) AND ANTIDE
PRESSANT

=> file biosis drugu embase uspatfull pctfull
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
6.10	21.17

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 13:24:57 ON 14 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'DRUGU' ENTERED AT 13:24:57 ON 14 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 13:24:57 ON 14 JUL 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 13:24:57 ON 14 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:24:57 ON 14 JUL 2006
COPYRIGHT (C) 2006 Univentio

=> s (E1-E8) and ((SSRI) or (serotonin(w)reuptake(w)inhibitor))
L4 181 ((ABILIFY/BI OR ABILITAT/BI OR ARIPIRAZOLE/BI OR "OPC 14597"/BI
OR "OPC 31"/BI OR 129722-12-9/BI OR 156680-99-8/BI OR "7-(4-(4-
(2,3-DICHLOROPHENYL)-1-PIPERAZINYL) BUTOXY)-3,4-DIHYDROCARBOSTYRIL
"/BI)) AND ((SSRI) OR (SEROTONIN(W) REUPTAKE(W) INHIBITOR))

=> dup rem L4
PROCESSING COMPLETED FOR L4
L5 175 DUP REM L4 (6 DUPLICATES REMOVED)

=> s l5 not py>2002
L6 2 L5 NOT PY>2002

=> d L6 1-2 ti

L6 ANSWER 1 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS
TIFR DERIVES DE CYCLOPROPYLINDOLE UTILISES EN TANT QU'INHIBITEURS SELECTIFS
DE RECAPTAGE DE LA SEROTONINE

L6 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN NEW DRUG COMBINATIONS
TIFR NOUVELLES COMBINAISONS MEDICAMENTEUSES

=> d L6 1-2 ti abs bib

L6 ANSWER 1 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS
TIFR DERIVES DE CYCLOPROPYLINDOLE UTILISES EN TANT QU'INHIBITEURS SELECTIFS
DE RECAPTAGE DE LA SEROTONINE
ABEN The present invention relates to compounds of Formula (I) and
pharmaceutically acceptable
salts or solvates thereof and pharmaceutically acceptable formulaitons
comprising
said compounds useful for the treatment of depression, anxiety
disorders, premature
ejaculation, chronic pain, obsessive-compulsive disorder, feeding
disorders,
premenstrual dysphoric disorder, panic disorders and psychotic disorders
including bipolar disorder and schizophrenia.
ABFR L'invention concerne des composes de formula (I) et leurs sels ou

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
14.86	15.07

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DDFU,
DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODBASE,
IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI,
MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 13:18:54 ON 14 JUL 2006

95 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (E1-E8) and antidepressant

2	FILE ADISCTI
1	FILE ADISINSIGHT
2	FILE ADISNEWS
23	FILE BIOSIS
1	FILE BIOTECHNO
15	FILE CAPLUS
37	FILE DDFU
8 FILES SEARCHED...	
43	FILE DRUGU
260	FILE EMBASE
1	FILE ESBIODBASE
16 FILES SEARCHED...	
10	FILE IFIPAT
3	FILE IPA
1	FILE JICST-EPLUS
1	FILE LIFESCI
8	FILE MEDLINE
6	FILE NLDB
7	FILE PASCAL
28 FILES SEARCHED...	
4	FILE PHARMAML
7	FILE PHIN
9	FILE SCISEARCH
17	FILE TOXCENTER
59	FILE USPATFULL
3	FILE USPAT2
38 FILES SEARCHED...	
1	FILE CABA
50 FILES SEARCHED...	
15	FILE PROMT
64 FILES SEARCHED...	
37	FILE WPIDS
69 FILES SEARCHED...	
1	FILE WPIFV
37	FILE WPINDEX
71 FILES SEARCHED...	
5	FILE EPFULL
1	FILE FRFULL
78 FILES SEARCHED...	
87 FILES SEARCHED...	
89 FILES SEARCHED...	
92	FILE PCTFULL
92 FILES SEARCHED...	

31 FILES HAVE ONE OR MORE ANSWERS, 95 FILES SEARCHED IN STNINDEX


L3 QUE ((ABILIFY/BI OR ABILITAT/BI OR ARIPIPRAZOLE/BI OR "OPC 14597"/BI OR "O
PC 31"/BI OR 129722-12-9/BI OR 156680-99-8/BI OR "7-(4-(4-(2,3-DICHLOR

290 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
293 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s clomipramine/cn
L2 1 CLOMIPRAMINE/CN

=> d L2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 303-49-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 5H-Dibenz[b,f]azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5H-Dibenz[b,f]azepine, 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-
(6CI, 7CI, 8CI)
OTHER NAMES:
CN 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine
CN Chlorimipramine
CN Clomipramine
CN G 34586
CN NSC 169865
FS 3D CONCORD
DR 83162-38-3
MF C19 H23 Cl N2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM,
DDFU, DRUGU, EMBASE, IMSPATENTS, IPA, MEDLINE, MRCK*, PROMT, PS, RTECS*,
SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2271 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2277 REFERENCES IN FILE CAPLUS (1907 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> sel L1
E1 THROUGH E8 ASSIGNED

=> sel L2
E9 THROUGH E15 ASSIGNED

=> index medicine bioscience patents

solvates
 acceptables sur le plan pharmaceutique ainsi que des preparations
 acceptables
 sur le plan pharmaceutique contenant ces composees utiles dans le
 traitement
 de la depression, de troubles d'anxiete, de l'ejaculation
 precoce, de douleur chronique, de trouble obsessionnel-compulsif, de
 troubles de l'alimentation, de trouble dysphorique premenstruel,
 de panique et de troubles psychotiques, notamment la maladie affective
 bipolaire
 et la schizophrénie.

AN 2002079152 PCTFULL ED 20021022 EW 200241
 TIEN CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS
 TIFR DERIVES DE CYCLOPROPYLINDOLE UTILISES EN TANT QU'INHIBITEURS SELECTIFS
 DE RECAPTAGE DE LA SEROTONINE
 IN MATTSON, Ronald, 65 Smithfield Avenue, Meriden, CT 06451, US [US, US];
 DENHART, Derek, 188 North Whittlesey Avenue, Wallingford, CT 06492, US
 [CA, US];
 DESKUS, Jeffrey, 82 Stage Harbor Road, Marlborough, CT 06447, US [US,
 US];
 DITTA, Jonathan, 51 Russett Lane, Middletown, CT 06457, US [US, US];
 MARCIN, Lawrence, 81 Peck Road, Bethany, CT 06524, US [US, US];
 EPPERSON, James, 5 Arrowwood Drive, Cromwell, CT 06416, US [US, US];
 CATT, John, 6633 Cheshire Drive, Newburgh, IN 47630, US [US, US];
 KING, Dalton, 114 Wakefield Street, Hamden, CT 06517, US [US, US];
 HIGGINS, Mendi, 8105 Town Ridge, Middletown, CT 06457, US [US, US]
 PA BRISTOL-MYERS SQUIBB COMPANY, P. O. Box 4000, Lawrenceville-Princeton
 Road, Princeton, NJ 08543-4000, US [US, US], for all designates States
 except US;
 MATTSON, Ronald, 65 Smithfield Avenue, Meriden, CT 06451, US [US, US],
 for US only;
 DENHART, Derek, 188 North Whittlesey Avenue, Wallingford, CT 06492, US
 [CA, US], for US only;
 DESKUS, Jeffrey, 82 Stage Harbor Road, Marlborough, CT 06447, US [US,
 US], for US only;
 DITTA, Jonathan, 51 Russett Lane, Middletown, CT 06457, US [US, US], for
 US only;
 MARCIN, Lawrence, 81 Peck Road, Bethany, CT 06524, US [US, US], for US
 only;
 EPPERSON, James, 5 Arrowwood Drive, Cromwell, CT 06416, US [US, US], for
 US only;
 CATT, John, 6633 Cheshire Drive, Newburgh, IN 47630, US [US, US], for US
 only;
 KING, Dalton, 114 Wakefield Street, Hamden, CT 06517, US [US, US], for
 US only;
 HIGGINS, Mendi, 8105 Town Ridge, Middletown, CT 06457, US [US, US], for
 US only
 AG MAKUJINA, Shah, BRISTOL-MYERS SQUIBB COMPANY, P. O. Box 4000,
 Lawrenceville-Princeton Road, Princeton, NJ 08543-4000, US
 LAF English
 LA English
 DT Patent
 PI WO 2002079152 A1 20021010
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
 TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2002-US6627 A 20020305
 PRAI US 2001-60/279,888 20010329
 US 2001-60/293,122 20010523

L6 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN NEW DRUG COMBINATIONS
 TIFR NOUVELLES COMBINAISONS MEDICAMENTEUSES
 ABEN A composition comprising: (a) a pharmaceutically effective amount of one or more norepinephrine reuptake inhibitors or a pharmaceutically effective salt thereof; and (b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof is provided. The composition is useful in treating disorders or diseases of the central nervous system, and particularly useful in treating schizophrenia.

ABFR L'invention concerne une composition renfermant: (a) une quantite efficace sur le plan pharmaceutique d'un ou plusieurs inhibiteurs de la reabsorption de la norepinephrine ou une quantite efficace sur le plan pharmaceutique de sel de celle-ci; et (b) une quantite efficace sur le plan pharmaceutique d'un ou plusieurs agents neuroleptiques ou une quantite efficace sur le plan pharmaceutique de ceux-ci. La composition est utile dans le traitement de troubles ou de maladies du systeme nerveux central, et notamment dans le traitement de la schizophrenie.

AN 2002053140 PCTFULL ED 20020723 EW 200228
 TIEN NEW DRUG COMBINATIONS
 TIFR NOUVELLES COMBINAISONS MEDICAMENTEUSES
 IN WONG, Erik, Ho, Fong, 7352 Hampstead Lane, Portage, MI 49024, US [US, US];
 GALLEN, Christopher, C., 8 Overbrook Parkway, Wynnewood, PA 19096, US [US, US];
 SVENSSON, Torgny, Ringvaegen 9, S-181 33 Lidingoe, SE [SE, SE]
 PA PHARMACIA & UPJOHN COMPANY, 301 Henrietta Street, Kalamazoo, MI 49001, US [US, US], for all designates States except US;
 PHARMACIA AB, Lindhagensgatan 133, S-0112 87 Stockholm, SE [SE, SE], for all designates States except US;
 WONG, Erik, Ho, Fong, 7352 Hampstead Lane, Portage, MI 49024, US [US, US], for US only;
 GALLEN, Christopher, C., 8 Overbrook Parkway, Wynnewood, PA 19096, US [US, US], for US only;
 SVENSSON, Torgny, Ringvaegen 9, S-181 33 Lidingoe, SE [SE, SE], for US only

AG NESBITT, Stephen, L., Pharmacia & Upjohn Company, Global Intellectual Property, 301 Henrietta Street, Kalamazoo, MI 49001, US
 LAF English
 LA English
 DT Patent
 PI WO 2002053140 A2 20020711
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
 TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2001-US45871 A 20011227
 PRAI US 2001-60/259,286 20010102

=> index medicine bioscience patents

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
10.32	31.49

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DDFU,

DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODBASE,
IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI,
MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 13:28:07 ON 14 JUL 2006

95 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (E9-E15) and (atypical(w)antipsychotic)

```
14  FILE ADISCTI
1   FILE ADISINSIGHT
4   FILE BIOSIS
6   FILE CAPLUS
4   FILE DDFU
9  FILES SEARCHED...
5   FILE DRUGU
144 FILE EMBASE
2   FILE ESBIODBASE
3   FILE IFIPAT
1   FILE IPA
2   FILE JICST-EPLUS
22 FILES SEARCHED...
4   FILE MEDLINE
1   FILE NLDB
3   FILE PASCAL
29 FILES SEARCHED...
6   FILE SCISEARCH
8   FILE TOXCENTER
36  FILE USPATFULL
3   FILE USPAT2
43 FILES SEARCHED...
64 FILES SEARCHED...
2   FILE WPIDS
69 FILES SEARCHED...
2   FILE WPINDEX
71 FILES SEARCHED...
1   FILE EPFULL
80 FILES SEARCHED...
89 FILES SEARCHED...
19  FILE PCTFULL
```

22 FILES HAVE ONE OR MORE ANSWERS, 95 FILES SEARCHED IN STNINDEX

L7 QUE ((CHLORIMIPRAMINE/BI OR CLOMIPRAMINE/BI OR "G 34586"/BI OR "NSC 169865
"/BI OR "3-CHLORO-5-(3-(DIMETHYLAMINO)PROPYL)-10,11-DIHYDRO-5H-DIBENZ(
B,F)AZEPINE"/BI OR 303-49-1/BI OR 83162-38-3/BI)) AND (ATYPICAL(W) ANT
IPSYCHOTIC)

=> file embase uspatfull pctfull

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
4.27	35.76

FULL ESTIMATED COST

FILE 'EMBASE' ENTERED AT 13:32:02 ON 14 JUL 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 13:32:02 ON 14 JUL 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:32:02 ON 14 JUL 2006

COPYRIGHT (C) 2006 Univentio

=> s (E9-E15) and (atypical(w)antipsychotic)

L8 199 ((CHLORIMIPRAMINE/BI OR CLOMIPRAMINE/BI OR "G 34586"/BI OR "NSC

169865"/BI OR "3-CHLORO-5-(3-(DIMETHYLAMINO)PROPYL)-10,11-DIHYDRO-5H-DIBENZ(B,F)AZEPINE"/BI OR 303-49-1/BI OR 83162-38-3/BI))
AND (ATYPICAL(W) ANTIPSYCHOTIC)

=> s l8 not py>2002

L9 41 L8 NOT PY>2002

=> dup rem L9

PROCESSING COMPLETED FOR L9

L10 40 DUP REM L9 (1 DUPLICATE REMOVED)

=> d L10 1-40 ti

L10 ANSWER 1 OF 40 USPATFULL on STN

TI Combination treatment for depression, anxiety and psychosis

L10 ANSWER 2 OF 40 USPATFULL on STN

TI Methods for treating neuropsychiatric disorders

L10 ANSWER 3 OF 40 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS

TIFR PERSONNALISATION D'UNE THERAPIE AVEC DES ANTIPSYCHOTIQUES

L10 ANSWER 4 OF 40 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS

TIFR ADAPTATION A L'INDIVIDU D'UN TRAITEMENT AUX ANTIPSYCHOTIQUES

L10 ANSWER 5 OF 40 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN ANTICONVULSANT DERIVATIVES USEFUL FOR THE TREATMENT OF DEPRESSION

TIFR DERIVES ANTICONVULSIVANTS UTILISES DANS LE TRAITEMENT DE LA DEPRESSION

L10 ANSWER 6 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI An open study of olanzapine and fluoxetine for psychotic major depressive disorder: Interim analyses.

L10 ANSWER 7 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Obsessive-compulsive-bipolar comorbidity: A systematic exploration of clinical features and treatment outcome.

L10 ANSWER 8 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI The autistic spectrum: Subgroups, boundaries, and treatment.

L10 ANSWER 9 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI The pharmacological treatment of autistic spectrum disorders.

L10 ANSWER 10 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI National Trends in the Use of Psychotropic Medications by Children.

L10 ANSWER 11 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Optimal dosing of atypical antipsychotics in adults: A review of the current evidence.

L10 ANSWER 12 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI An overview of trichotillomania and its response to treatment with quetiapine.

L10 ANSWER 13 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Efficacy of clozapine in a non-schizophrenic patient with psychogenic polydipsia and central pontine myelinolysis.

L10 ANSWER 14 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Psychopharmacology for individuals with autism spectrum disorders.

L10 ANSWER 15 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI The Neuroleptic Malignant and Serotonin Syndromes.

L10 ANSWER 16 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Risperidone in the treatment of psychoses in the elderly: A case report series.

L10 ANSWER 17 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Olanzapine augmentation in the treatment of melancholia: The trajectory of improvement in rapid responders.

L10 ANSWER 18 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Quetiapine augmentation of serotonin reuptake inhibitors in obsessive - Compulsive disorder.

L10 ANSWER 19 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Treatment strategies in achieving remission in major depressive disorder. DUPLICATE 1

L10 ANSWER 20 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Treatment of psychosis, aggression, and irritability in patients with epilepsy.

L10 ANSWER 21 OF 40 USPATFULL on STN

TI Methods for treating neuropsychiatric disorders

L10 ANSWER 22 OF 40 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN DIAGNOSIS OF BIPOLAR AFFECTIVE DISORDER (BAD) AND UNIPOLAR DEPRESSION

TIFR PROTEINES, GENES ET LEUR UTILISATION DANS LE DIAGNOSTIC ET LE TRAITEMENT DE MALADIES AFFECTIVES BIPOLAIRES (BAD) ET DE DEPRESSIONS UNIPOLAIRES

L10 ANSWER 23 OF 40 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN DIAGNOSIS AND TREATMENT OF BIPOLAR AFFECTIVE DISORDER

TIFR DIAGNOSTIC ET TRAITEMENT DE LA MALADIE AFFECTIVE BIPOLAIRE

L10 ANSWER 24 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Pharmacological options for the treatment of Tourette's disorder.

L10 ANSWER 25 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Pharmacotherapy for post-traumatic stress disorder: A comprehensive review.

L10 ANSWER 26 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI An evaluation of risperidone drug interactions.

L10 ANSWER 27 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI [Fifty years of antipsychotic drugs in psychiatry: II - Piperazine phenothiazines].
CINQUENTA ANOS DE MEDICAMENTOS ANTIPSICOTICOS EM PSIQUIATRIA: II.

FENOTIAZINAS PIPERAZINICAS.

L10 ANSWER 28 OF 40 USPATFULL on STN
TI Serotonin 5-HT6 receptor knockout mouse

L10 ANSWER 29 OF 40 USPATFULL on STN
TI Substituted pyridylamino indoles

L10 ANSWER 30 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Serotonin and dopamine antagonism in obsessive-compulsive disorder: Effect of atypical antipsychotic drugs.

L10 ANSWER 31 OF 40 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS
TIFR METHODES DE TRAITEMENT DE TROUBLES NEUROPSYCHIATRIQUES

L10 ANSWER 32 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Separation anxiety in children and adolescents treated with risperidone.

L10 ANSWER 33 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Case studies on the use of risperidone for the treatment of agitation in elderly patients with dementia.

L10 ANSWER 34 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Response of a patient with Lewy-body dementia to risperidone.

L10 ANSWER 35 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Future therapies of Tourette syndrome.

L10 ANSWER 36 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Psychopharmacologic treatment of pathologic aggressio n.

L10 ANSWER 37 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Risperidone in the treatment of affective illness and obsessive-compulsive disorder.

L10 ANSWER 38 OF 40 USPATFULL on STN
TI Substituted (pyridinylamino)-indoles

L10 ANSWER 39 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI The discriminative stimulus effects of clozapine in pigeons: Involvement of 5-hydroxytryptamine(1C) and 5-hydroxytryptamine2 receptors.

L10 ANSWER 40 OF 40 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Suitability of amfonelic acid-induced locomotor stimulation in mice as a model for the evaluation of classical and atypical antipsychotics.

=> s l10 nad (depression or smoking)
MISSING OPERATOR L10 NAD
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l10 and (depression or smoking)
L11 21 L10 AND (DEPRESSION OR SMOKING)

=> d L11 1-21 ti

L11 ANSWER 1 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI National Trends in the Use of Psychotropic Medications by Children.

L11 ANSWER 2 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI The pharmacological treatment of autistic spectrum disorders.

L11 ANSWER 3 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Treatment strategies in achieving remission in major depressive disorder.

L11 ANSWER 4 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI An open study of olanzapine and fluoxetine for psychotic major depressive disorder: Interim analyses.

L11 ANSWER 5 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Obsessive-compulsive-bipolar comorbidity: A systematic exploration of clinical features and treatment outcome.

L11 ANSWER 6 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Psychopharmacology for individuals with autism spectrum disorders.

L11 ANSWER 7 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Olanzapine augmentation in the treatment of melancholia: The trajectory of improvement in rapid responders.

L11 ANSWER 8 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Psychopharmacologic treatment of pathologic aggression.

L11 ANSWER 9 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Future therapies of Tourette syndrome.

L11 ANSWER 10 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Risperidone in the treatment of affective illness and obsessive-compulsive disorder.

L11 ANSWER 11 OF 21 USPATFULL on STN
TI Combination treatment for depression, anxiety and psychosis

L11 ANSWER 12 OF 21 USPATFULL on STN
TI Methods for treating neuropsychiatric disorders

L11 ANSWER 13 OF 21 USPATFULL on STN
TI Methods for treating neuropsychiatric disorders

L11 ANSWER 14 OF 21 USPATFULL on STN
TI Substituted pyridylamino indoles

L11 ANSWER 15 OF 21 USPATFULL on STN
TI Substituted (pyridinylamino)-indoles

L11 ANSWER 16 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS
TIFR PERSONNALISATION D'UNE THERAPIE AVEC DES ANTIPSYCHOTIQUES

L11 ANSWER 17 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS
 TIFR ADAPTATION A L'INDIVIDU D'UN TRAITEMENT AUX ANTIPSYCHOTIQUES

L11 ANSWER 18 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN ANTICONVULSANT DERIVATIVES USEFUL FOR THE TREATMENT OF
 DEPRESSION
 TIFR DERIVES ANTICONVULSIVANTS UTILISES DANS LE TRAITEMENT DE LA
 DEPRESSION

L11 ANSWER 19 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN DIAGNOSIS OF BIPOLAR AFFECTIVE DISORDER (BAD) AND UNIPOLAR
 DEPRESSION
 TIFR PROTEINES, GENES ET LEUR UTILISATION DANS LE DIAGNOSTIC ET LE TRAITEMENT
 DE MALADIES AFFECTIVES BIPOLAIRES (BAD) ET DE DEPRESSIONS UNIPOLAIRES

L11 ANSWER 20 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN DIAGNOSIS AND TREATMENT OF BIPOLAR AFFECTIVE DISORDER
 TIFR DIAGNOSTIC ET TRAITEMENT DE LA MALADIE AFFECTIVE BIPOLAIRE

L11 ANSWER 21 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS
 TIFR METHODES DE TRAITEMENT DE TROUBLES NEUROPSYCHIATRIQUES

=> d L11 2 3 4 10 11 12 14 15 16 17 18 21 ti abs bib

L11 ANSWER 2 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
 reserved on STN
 TI The pharmacological treatment of autistic spectrum disorders.
 AB What role do medications play in the overall treatment of autistic
 spectrum disorders? In this review, the decision-making process involving
 identifying symptoms, initiating a pharmacological intervention, and
 monitoring that process is discussed. A review of the literature with an
 emphasis on controlled trials in autistic spectrum disorders is also
 undertaken.
 AN 2003254588 EMBASE
 TI The pharmacological treatment of autistic spectrum disorders.
 AU Owley T.
 CS Dr. T. Owley, University of Chicago, Department of Psychiatry, Division of
 Child Psychiatry, 5841 South Maryland Avenue, Chicago, IL 60637, United
 States. towley@yoda.bsd.uchicago.edu
 SO CNS Spectrums, (1 Sep 2002) Vol. 7, No. 9, pp. 663-669. .
 Refs: 88
 ISSN: 1092-8529 CODEN: CNSPFH
 CY United States
 DT Journal; General Review
 FS 032 Psychiatry
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LA English
 SL English
 ED Entered STN: 10 Jul 2003
 Last Updated on STN: 10 Jul 2003

L11 ANSWER 3 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
 reserved on STN
 TI Treatment strategies in achieving remission in major depressive disorder.
 AB Objective: This paper discusses strategies for achieving remission in
 major depressive disorder, summarizing the results of comparative studies
 of various antidepressants. Method: Antidepressant efficacy was
 determined as either response or remission, measured using the Hamilton
 Depression Rating Scale, the Clinical Global Impressions scale and
 other widely used instruments. Results: Study results suggest an
 advantage to pharmacotherapy that interacts with more than one

neurotransmitter system, either as single mixed-activity drugs (e.g. clomipramine, mirtazapine and venlafaxine extended-release) or combinations of medications that are individually specific for a single neurotransmitter system. Conclusion: Remission should be the goal of antidepressant therapy. Treatment strategies include increasing the dosage of the chosen antidepressant; switching to an antidepressant with a different mechanism of action; augmenting one antidepressant with another agent; or using combination therapy. A substantial body of data indicates that for a subset of depressed patients, activation of multiple neurotransmitter systems is beneficial in achieving remission.

AN 2003050969 EMBASE
TI Treatment strategies in achieving remission in major depressive disorder.
AU Kelsey J.E.
CS Dr. J.E. Kelsey, Georgia Inst. of Mood/Anxiety D., 7 Piedmont Center, 3525
Piedmont Road, Atlanta, GA 30325, United States. JEKelsey@bellsouth.net
SO Acta Psychiatrica Scandinavica, Supplement, (2002) Vol. 106, No. 415, pp.
18-23. .
Refs: 24
ISSN: 0065-1591 CODEN: ASSUA6
CY Denmark
DT Journal; Conference Article
FS 030 Pharmacology
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 7 Feb 2003
Last Updated on STN: 7 Feb 2003

L11 ANSWER 4 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI An open study of olanzapine and fluoxetine for psychotic major depressive disorder: Interim analyses.

AB Background: Although atypical antipsychotic agents are commonly used in the treatment of psychotic depression, there are no published prospective studies on their use in this condition. The aim of this study was to assess, by interim analyses, the efficacy of the atypical antipsychotic agent olanzapine in combination with the selective serotonin reuptake inhibitor antidepressant agent fluoxetine. Method: We enrolled 27 patients (17 women [63.0%] and 10 men [37.0%]; mean \pm SD age: 41.2 \pm 14.7 years) with DSM-IV-defined major depressive disorder with psychotic features into an open trial of olanzapine, 5 to 20 mg/day, plus fluoxetine, 20 to 80 mg/day. Patients were assessed at each visit with the 17-item Hamilton Rating Scale for Depression and both the psychotic and mood modules of the Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition. We are reporting the results of the first 6 weeks of treatment. Results: Twenty-two (81.5%) of the 27 enrolled patients completed the 6-week open trial, and 5 (18.5%) dropped out, with only 2 (7.4%) dropping out due to side effects. Of the 27 patients, 74.1% (N = 20) met criteria for melancholic features, 14.8% (N = 4) had delusions alone, 18.5% (N = 5) had hallucinations alone, and 66.7% (N = 18) reported both delusions and hallucinations. In addition, the overall rates of response for the intent-to-treat group were as follows: depression response rate, 66.7% (N = 18); psychosis response rate, 59.3% (N = 16); psychotic depression response rate, 55.6% (N = 15); and psychotic depression remission rate, 40.7% (N = 11). Conclusion: The combination of olanzapine and fluoxetine appears to be a promising, safe, and effective treatment for psychotic depression. Double-blind studies are needed to confirm this impression.

AN 2003031917 EMBASE
TI An open study of olanzapine and fluoxetine for psychotic major depressive disorder: Interim analyses.
AU Matthews J.D.; Bottonari K.A.; Polania L.M.; Mischoulon D.; Dording C.M.;

Irvin R.; Fava M.
 CS jmatthews@partners.org
 SO Journal of Clinical Psychiatry, (2002) Vol. 63, No. 12, pp. 1164-1170. .
 Refs: 54
 ISSN: 0160-6689 CODEN: JCLPDE
 CY United States
 DT Journal; Article
 FS 032 Psychiatry
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LA English
 SL English
 ED Entered STN: 30 Jan 2003
 Last Updated on STN: 30 Jan 2003

L11 ANSWER 10 OF 21 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
 AB Background: Risperidone is a new-generation atypical antipsychotic agent with potent dopaminergic and serotonergic antagonist activity. Compared with traditional dopamine-blocking neuroleptics, risperidone is more effective in treating negative symptoms of schizophrenia and may be less likely to cause extrapyramidal symptoms or tardive dyskinesia. Although risperidone is marketed for the treatment of schizophrenia, its novel psychopharmacologic effects and potentially mild side effect profile suggest the possibility of other therapeutic applications. An open prospective study was undertaken to determine whether risperidone might diminish psychosis, severe agitation, or rapid cycling in patients having acute and chronic primary affective illnesses (bipolar and major depressive disorder) and to document response characteristics and side effects. Additionally, a small number of patients with refractory obsessive-compulsive disorder (OCD) without comorbid tic or delusional disorders were given open trials of risperidone added to their medication. Method: Outpatients who fulfilled DSM-IV criteria for bipolar I, bipolar II, or major depressive disorder and suffered from psychosis or agitation associated with their illness (N = 20) and those who had treatment-refractory DSM-IV OCD (N = 5) were started on open trials of risperidone at daily doses of 1 to 1.5 mg. Doses were adjusted upwards to a maximum of 6 mg depending on clinical response. Results: Seventeen (85%) of 20 patients (13 bipolar, 4 major depressive disorder) showed complete or partial improvement after treatment with risperidone doses ranging from 1 to 6 mg/day (mean = 3.5 mg). Beneficial effects included decreases in agitation, psychosis, sleep disturbance, and rapid cycling. Four patients (20%) discontinued risperidone because of intolerable side effects. Five patients with refractory OCD also showed significant symptomatic improvement after the addition of risperidone. Conclusion: The findings suggest that (1) risperidone may be useful in the acute/p.r.n. and chronic treatment of psychosis, agitation, and cycling accompanying affective illness, and (2) risperidone may be useful in augmenting pharmacologic response in OCD.
 AN 95289514 EMBASE
 DN 1995289514
 TI Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
 AU Jacobsen F.M.
 CS Transcultural Mental Health Inst., 1301 20th Street, N.W., Washington, DC 20036-6043, United States
 SO Journal of Clinical Psychiatry, (1995) Vol. 56, No. 7 SUPPL., pp. 423-429.
 .
 ISSN: 0160-6689 CODEN: JCLPDE
 CY United States
 DT Journal; Article
 FS 032 Psychiatry
 037 Drug Literature Index

038 Adverse Reactions Titles

LA English
SL English
ED Entered STN: 9 Nov 1995
Last Updated on STN: 9 Nov 1995

L11 ANSWER 11 OF 21 USPATFULL on STN

TI Combination treatment for depression, anxiety and psychosis
AB The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:179195 USPATFULL
TI Combination treatment for depression, anxiety and psychosis
IN Chappell, Phillip Branch, Guilford, CT, UNITED STATES
Zorn, Stevin Howard, North Stonington, CT, UNITED STATES
PA Pfizer Inc (U.S. corporation)
PI US 2002094986 A1 20020718
AI US 2001-1827 A1 20011205 (10)
PRAI US 2000-251284P 20001205 (60)
DT Utility
FS APPLICATION
LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2599

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 21 USPATFULL on STN

TI Methods for treating neuropsychiatric disorders
AB The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) a therapeutically effective amount of D-alanine (or a modified form thereof), provided that the composition is substantially free of D-cycloserine, and/or (ii) D-serine (or a modified form thereof), and/or (iii) 105 to 500 mg of D-cycloserine (or a modified form thereof), and/or (iv) N-methylglycine (or a modified form thereof).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:61309 USPATFULL
TI Methods for treating neuropsychiatric disorders
IN Tsai, Guochuan, Cambridge, MA, UNITED STATES
Coyle, Joseph, Belmont, MA, UNITED STATES
PA The General Hospital Corporation (U.S. corporation)
PI US 2002035145 A1 20020321
US 6420351 B2 20020716
AI US 2001-834351 A1 20010413 (9)
RLI Continuation of Ser. No. US 1999-291296, filed on 14 Apr 1999, GRANTED, Pat. No. US 6228875
PRAI US 1998-81645P 19980414 (60)
DT Utility
FS APPLICATION
LREP JANIS K. FRASER, PH.D., J.D., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 38

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 21 USPATFULL on STN
TI Substituted pyridylamino indoles
AB There are disclosed various compounds of the formula below, ##STR1##
where R, R.sub.1, W, X, Y and Z are as defined in the specification;
which are useful for alleviating various memory dysfunctions such as
Alzheimer's disease, as modulators of neurotransmitter functions such as
serotonergic and adrenergic, and as such are useful as antidepressants,
anxiolytics, atypical antipsychotics, antienmtics, and for the treatment
of personality disorders such as obsessive compulsive disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:15656 USPATFULL
TI Substituted pyridylamino indoles
IN Effland, Richard Charles, Bridgewater, NJ, United States
Klein, Joseph Thomas, Bridgewater, NJ, United States
Martin, Lawrence Leo, Lebanon, NJ, United States
Shutske, Gregory M., Flemington, NJ, United States
Kapples, Kevin J., Little York, NJ, United States
Tomer, IV, John D., Perkasio, PA, United States
PA Hoechst Marion Roussel, Inc., Bridgewater, NJ, United States (U.S.
corporation)
PI US 6022880 20000208
AI US 1997-901557 19970728 (8)
RLI Continuation of Ser. No. US 1960-227757, filed on 14 Apr 1960, now
abandoned which is a division of Ser. No. US 1992-964546, filed on 21
Oct 1992, now patented, Pat. No. US 5328920 which is a
continuation-in-part of Ser. No. US 1991-688964, filed on 17 Apr 1991,
now patented, Pat. No. US 5177088
DT Utility
FS Granted
EXNAM Primary Examiner: Fan, Jane
LREP Balaram Gupta
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3272
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 21 USPATFULL on STN
TI Substituted (pyridinylamino)-indoles
AB There are disclosed various compounds of the formula below, ##STR1##
where R, R.sub.1, W, X, Y and Z are as defined in the specification;
which are useful for alleviating various memory dysfunctions such as
Alzheimer's disease, as modulators of neurotransmitter functions such as
serotonergic and adrenergic, and as such are useful as antidepressants,
anxiolytics, atypical antipsychotics, antiemetics, and for the treatment
of personality disorders such as obsessive compulsive disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 94:60171 USPATFULL
TI Substituted (pyridinylamino)-indoles
IN Effland, Richard C., Bridgewater, NJ, United States
Klein, Joseph T., Bridgewater, NJ, United States
Martin, Lawrence L., Lebanon, NJ, United States
Shutske, Gregory M., Flemington, NJ, United States
Kapples, Kevin J., Little York, NJ, United States
Tomer, IV, John D., Perkasio, PA, United States
PA Hoechst-Roussel Pharmaceuticals Incorporated, Somerville, NJ, United
States (U.S. corporation)
PI US 5328920 19940712

AI US 1992-964546 19921021 (7)
DCD 20100105
RLI Continuation-in-part of Ser. No. US 1991-688964, filed on 17 Apr 1991,
now patented, Pat. No. US 5177088
DT Utility
FS Granted
EXNAM Primary Examiner: Fan, Jane T.
LREP Ikeda, Tatsuya
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2977
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS
TIFR PERSONNALISATION D'UNE THERAPIE AVEC DES ANTIPSYCHOTIQUES
ABEN The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with antipsychotic agents.
ABFR L'invention concerne la personnalisation d'une therapie en fonction d'un
profil phenotypique d'un individu. Plus specifiquement, l'invention
concerne la determination du phenotype metabolique pour la
personnalisation d'un traitement avec des agents antipsychotiques.
AN 2002073206 PCTFULL ED 20020927 EW 200238
TIEN INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS
TIFR PERSONNALISATION D'UNE THERAPIE AVEC DES ANTIPSYCHOTIQUES
IN LEYLAND-JONES, Brian, 80 S. W. 8th Street, Suite 2000, Miami, FL 33130,
US [CA, US]
PA MCGILL UNIVERSITY, 845 Sherbrooke Street West, Montreal, Quebec H3A 2T5,
CA [CA, CA], for all designates States except US;
LEYLAND-JONES, Brian, 80 S. W. 8th Street, Suite 2000, Miami, FL 33130,
US [CA, US], for US only
AG COTE, France, Ogilvy Renault, Suite 1600, 1981 McGill College Avenue,
Montreal, Quebec H3A 2Y3, CA
LAF English
LA English
DT Patent
PI WO 2002073206 A2 20020919
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-CA362 A 20020314
PRAI US 2001-60/275,493 20010314

L11 ANSWER 17 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS
TIFR ADAPTATION A L'INDIVIDU D'UN TRAITEMENT AUX ANTIPSYCHOTIQUES
ABEN The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with antipsychotic agents.
ABFR L'invention concerne l'adaptation a l'individu d'un traitement,
effectuee sur la base du profil phenotypique de l'individu. Elle
concerne plus particulierement l'utilisation du phenotypage metabolique
a des fins d'adaptation a l'individu d'un traitement aux
antipsychotiques.
AN 2002073196 PCTFULL ED 20020927 EW 200238

TIEN INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS
 TIFR ADAPTATION A L'INDIVIDU D'UN TRAITEMENT AUX ANTIPSYCHOTIQUES
 IN LEYLAND-JONES, Brian, 80 S.W. 8th Street, Suite 2000, Miami, FL 33130, US [CA, US]
 PA MCGILL UNIVERSITY, 845 Sherbrooke Street West, Montreal, Quebec H3A 2T5, CA [CA, CA], for all designates States except US;
 LEYLAND-JONES, Brian, 80 S.W. 8th Street, Suite 2000, Miami, FL 33130, US [CA, US], for US only
 AG OGILVY RENAULT, Suite 1600, 1981 McGill College Avenue, Montreal, Quebec H3A 2Y3, CA
 LAF English
 LA English
 DT Patent
 PI WO 2002073196 A2 20020919
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
 TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2002-CA343 A 20020314
 PRAI US 2001-60/275,462 20010314

 L11 ANSWER 18 OF 21 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN ANTICONVULSANT DERIVATIVES USEFUL FOR THE TREATMENT OF
 DEPRESSION
 TIFR DERIVES ANTICONVULSIVANTS UTILISES DANS LE TRAITEMENT DE LA
 DEPRESSION
 ABEN Anticonvulsant derivatives of formula (I) for the treating
 depression as monotherapy or combination therapy are disclosed.
 Wherein X is CH₂ or oxygen; R₁ is hydrogen or alkyl; and R₂, R₃, R₄ and
 R₅ are independently hydrogen or lower alkyl and, when X is CH₂, R₄ and
 R₅ may be alkene groups joined to form a benzene ring and, when X is
 oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy
 group of the following formula (II): wherein R₆ and R₇ are the same or
 different and are hydrogen, lower alkyl or are alkyl and are joined to
 form a cyclopentyl or cyclohexyl ring.
 ABFR La presente invention concerne des derives anticonvulsivants representes
 par la formule (I), utilisees en monotherapie ou en polytherapie pour
 traiter la depression. Dans cette formule, X represente CH₂ ou
 oxygene; R₁ represente hydrogene ou alkyle; et R₂, R₃, R₄ et R₅
 representent individuellement hydrogene ou alkyle inferieur, et, lorsque
 X represente CH₂, R₄ et R₅ peuvent représenter des groupes alcenes lies
 de facon a former un noyau benzene, et, lorsque X represente oxygene, R₂
 et R₃ et/ou R₄ et R₅ peuvent représenter un groupe methylenedioxy
 representes par la formule (II), dans laquelle R₆ et R₇ sont identiques
 ou differents et representent hydrogene ou alkyle inferieur, ou alors
 alkyle, et sont lies de facon a former un noyau cyclopentyle ou
 cyclohexyle.
 AN 2002009694 PCTFULL ED 20020814
 TIEN ANTICONVULSANT DERIVATIVES USEFUL FOR THE TREATMENT OF
 DEPRESSION
 TIFR DERIVES ANTICONVULSIVANTS UTILISES DANS LE TRAITEMENT DE LA
 DEPRESSION
 IN PLATA-SALAMAN, Carlos;
 BACALTCHUK, Josue;
 PRADO-LIMA, Pedro, A., S.
 PA ORTHO-MCNEIL PHARMACEUTICAL, INC.
 DT Patent
 PI WO 2002009694 A1 20020207
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN

IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
 TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG
 ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
 GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ
 GW ML MR NE SN TD TG

AI WO 2001-US23786 A 20010727
 PRAI US 2000-60/222,489 20000802

L11 ANSWER 21 OF 21 PCTFULL COPYRIGHT 2006 Univention on STN
 TIEN METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS
 TIFR METHODES DE TRAITEMENT DE TROUBLES NEUROPSYCHIATRIQUES
 ABEN The invention provides methods for treating neuropsychiatric disorders
 such as schizophrenia,
 Alzheimer's Disease, autism, depression, benign forgetfulness,
 childhood learning disorders, close
 head injury, and attention deficit disorder. The methods entail
 administering to a patient diagnosed
 as having a neuropsychiatric disorder a pharmaceutical composition
 containing (i) a therapeutically
 effective amount of D-alanine (or a modified form thereof), provided
 that the composition is
 substantially free of D-cycloserine, and/or (ii) D-serine (or a modified
 form thereof), and/or (iii)
 105 to 500 mg of D-cycloserine (or a modified form thereof), and/or (iv)
 N-methylglycine (or a
 modified form thereof).

ABFR L'invention concerne des methodes de traitement de troubles
 neuropsychiatriques tels que la
 schizophrénie, la maladie d'Alzheimer, l'autisme, la depression
 , les pertes de memoire benignes, les
 difficultes scolaires chez l'enfant, les lesions craniennes fermees et
 le trouble deficitaire de
 l'attention. Les methodes consistent a administrer a un patient, chez
 lequel on a diagnostique un
 trouble neuropsychiatrique, une composition pharmaceutique contenant :
 (i) une quantite efficace sur
 le plan therapeutique de D-alanine (ou une forme modifiee de D-alanine),
 a condition que la
 composition soit sensiblement exempte de D-cycloserine ; et/ou (ii)
 D-serine (ou une forme modifiee
 de D-serine) ; et/ou (iii) 105 a 500 mg de D-cycloserine (ou une forme
 modifiee de D-cycloserine) ;
 et/ou (iv) N-methylglycine (ou une forme modifiee de N-methylglycine).

AN 1999052519 PCTFULL ED 20020515
 TIEN METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS
 TIFR METHODES DE TRAITEMENT DE TROUBLES NEUROPSYCHIATRIQUES
 IN TSAI, Guochuan;
 COYLE, Joseph
 PA THE GENERAL HOSPITAL CORPORATION
 LA English
 DT Patent
 PI WO 9952519 A2 19991021
 DS W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD
 SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS
 MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
 CM GA GN GW ML MR NE SN TD TG

AI WO 1999-US8056 A 19990414
 PRAI US 1998-60/081,645 19980414

=> index medicine bioscience patents

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
36.01	71.77

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 13:36:12 ON 14 JUL 2006

95 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s smoking and (atypical(w)antipsychotic) and (antidepressant)

2	FILE ADISCTI
1	FILE ADISINSIGHT
3	FILE BIOSIS
1	FILE CAPLUS
2	FILE DRUGU
25	FILE EMBASE
2	FILE IFIPAT
1	FILE PASCAL
1	FILE PHIN
35	FILE USPATFULL
11	FILE USPAT2

43 FILES SEARCHED...

5	FILE PROMT
1	FILE PROUSDDR
1	FILE WPIDS
1	FILE WPINDEX
1	FILE EPFULL

81 FILES SEARCHED...

21	FILE PCTFULL
----	--------------

17 FILES HAVE ONE OR MORE ANSWERS, 95 FILES SEARCHED IN STNINDEX

L12 QUE SMOKING AND (ATYPICAL(W) ANTIPSYCHOTIC) AND (ANTIDEPRESSANT)

=> file embase uspatfull pctfull

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.05	74.82

FULL ESTIMATED COST

FILE 'EMBASE' ENTERED AT 13:39:07 ON 14 JUL 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 13:39:07 ON 14 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:39:07 ON 14 JUL 2006
COPYRIGHT (C) 2006 Univentio

=> s smoking and (atypical(w)antipsychotic) and (SSRI or (serotonin(w)reuptake) or (MAOI(w)inhibitor))

L13 55 SMOKING AND (ATYPICAL(W) ANTIPSYCHOTIC) AND (SSRI OR (SEROTONIN(W) REUPTAKE) OR (MAOI(W) INHIBITOR))

=> s L13 not py>2002

L14 3 L13 NOT PY>2002

=> dup rem L14

PROCESSING COMPLETED FOR L14

L15 3 DUP REM L14 (0 DUPLICATES REMOVED)

=> d L15 1-3 ti

L15 ANSWER 1 OF 3 USPATFULL on STN

TI Compositions and therapy for substance addiction

L15 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN QUINUCLIDINE-SUBSTITUTED HETERO-BICYCLIC AROMATIC COMPOUNDS FOR THE TREATMENT OF DISEASE

TIFR COMPOSES AROMATIQUES HETERO-BICYCLIQUES SUBSTITUES PAR QUINUCLIDINE DANS LE TRAITEMENT DE MALADIES

L15 ANSWER 3 OF 3 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Vascular dementia revisited: Diagnosis, pathogenesis, treatment, and prevention.

=> d L15 1-3 ti abs bib

L15 ANSWER 1 OF 3 USPATFULL on STN

TI Compositions and therapy for substance addiction

AB Inhibitors of monoamine oxidase used in combination with an addictive substance, or a pharmacological derivative or analogue thereof, are useful for the treatment of substance addiction disorders. In particular, the invention discloses compositions, and methods of use thereof, comprising selegiline and nicotine for the treatment of cigarette smokers wishing to abstain. The compositions and methods of use thereof include oral, inhalant, parenteral and transdermal patch modes of therapy, whereby the subject benefits from the combined effects of a monoamine oxidase inhibitor in combination with an addictive substance, or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:32599 USPATFULL

TI Compositions and therapy for substance addiction

IN Biberman, Roni, Tel-Aviv, ISRAEL

PI US 2002019421 A1 20020214

AI US 2001-898027 A1 20010705 (9)

PRAI US 2000-216366P 20000705 (60)

DT Utility

FS APPLICATION

LREP Eitan, Pearl, Latzer & Cohen-Zedek, One Crystal Park, Suite 210, 2011 Crystal Drive, Arlington, VA, 22202-3700

CLMN Number of Claims: 66

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2054

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN QUINUCLIDINE-SUBSTITUTED HETERO-BICYCLIC AROMATIC COMPOUNDS FOR THE TREATMENT OF DISEASE

TIFR COMPOSES AROMATIQUES HETERO-BICYCLIQUES SUBSTITUES PAR QUINUCLIDINE DANS LE TRAITEMENT DE MALADIES

ABEN The invention provides compounds of Formula (I): wherein W₀ is a bicyclic moiety and is (I). These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful to treat diseases or conditions in which α_7 is known to be involved.

ABFR La presente invention concerne des composés de la formule (1), dans

laquelle W?0 ?est un fragment bicyclique et est (1). Les
composes
de l'invention peuvent se presenter sous la forme de sels ou de
compositions

pharmaceutiques, sous une forme enantiomeriquement pure ou sous
la forme de melanges racemiques, et ils sont utilises pour traiter
des maladies ou des etats dans lesquels l'alpha7 est implique.

AN 2002100858 PCTFULL ED 20030102 EW 200251
TIEN QUINUCLIDINE-SUBSTITUTED HETERO-BICYCLIC AROMATIC COMPOUNDS FOR THE
TREATMENT OF DISEASE
TIFR COMPOSES AROMATIQUES HETERO-BICYCLIQUES SUBSTITUES PAR QUINUCLIDINE DANS
LE TRAITEMENT DE MALADIES
IN WALKER, Daniel, P., 9350 Highlandview Drive, Kalamazoo, MI 49009, US
[US, US];
WISHKA, Donn, G., 1431 Northampton Road, Kalamazoo, MI 49006-1993, US
[US, US];
CORBETT, Jeffrey, W., 6427 Pepperidge Circle, Portage, MI 49024, US [US,
US];
RAUCKHORST, Mark, R., 3749 Tartan Circle, Portage, MI 49024, US [US,
US];
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US,
US];
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US
[US, US]
PA PHARMACIA & UPJOHN COMPANY, 301 Henrietta Street, Kalamazoo, MI 49001,
US [US, US], for all designates States except US;
WALKER, Daniel, P., 9350 Highlandview Drive, Kalamazoo, MI 49009, US
[US, US], for US only;
WISHKA, Donn, G., 1431 Northampton Road, Kalamazoo, MI 49006-1993, US
[US, US], for US only;
CORBETT, Jeffrey, W., 6427 Pepperidge Circle, Portage, MI 49024, US [US,
US], for US only;
RAUCKHORST, Mark, R., 3749 Tartan Circle, Portage, MI 49024, US [US,
US], for US only;
PIOTROWSKI, David, W., 3248 Lost Pine Way, Portage, MI 49024, US [US,
US], for US only;
GROPPI, Vincent, E., Jr., 318 Sprague Avenue, Kalamazoo, MI 49006, US
[US, US], for US only
AG HOSLEY, Mary, J., Global Intellectual Property, Pharmacia & Upjohn
Company, 301 Henrietta Street, Kalamazoo, MI 49001, US
LAF English
LA English
DT Patent
PI WO 2002100858 A2 20021219
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-US16570 A 20020606
PRAI US 2001-60/297,629 20010612
US 2001-60/297,631 20010612
US 2001-60/297,630 20010612
US 2001-60/297,632 20010612
US 2001-60/297,633 20010612
US 2001-60/328,548 20011011
US 2002-60/373,496 20020418

L15 ANSWER 3 OF 3 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Vascular dementia revisited: Diagnosis, pathogenesis, treatment, and

prevention.

AB VaD is the second most common cause of dementia in the elderly after AD. VaD is defined as the loss of cognitive function resulting from ischemic, ischemic-hypoxic, or hemorrhagic brain lesions as a result of CVD and cardiovascular pathologic changes. Diagnosis requires (1) cognitive loss (often predominantly subcortical), (2) vascular brain lesions demonstrated by imaging, and (3) exclusion of other causes of dementia, such as AD. VaD is excluded by brain imaging showing no evidence of vascular lesions. VaD may be caused by multiple strokes (MID or poststroke dementia) but also by single strategic strokes, multiple lacunes, and hypoperfusive lesions such as border zone infarcts and ischemic periventricular leukoencephalopathy (Binswanger's disease). Primary and secondary prevention of stroke and cardiovascular disease decreases the burden of VaD. Genetic advice is needed in patients with familial forms, such as CADASIL. Treatment involves control of risk factors (ie, hypertension, diabetes, smoking, hyperfibrinogenemia, hyperhomocystinemia, orthostatic hypotension, cardiac arrhythmias). Anticholinergic medications used for AD are also useful in VaD, and atypical antipsychotic agents and antidepressants (eg, selective serotonin reuptake inhibitors) may be required in some patients.

AN 2002268991 EMBASE

TI Vascular dementia revisited: Diagnosis, pathogenesis, treatment, and prevention.

AU Roman G.C.

CS Dr. G.C. Roman, Department of Medicine, Univ. of Texas Health Science Center, Audie L. Murphy Mem. Veterans Hosp., 7703 Floyd Curl Drive, San Antonio, TX 78284-7883, United States. romang@uthscsa.edu

SO Medical Clinics of North America, (2002) Vol. 86, No. 3, pp. 477-499. . Refs: 155

ISSN: 0025-7125 CODEN: MCNAA

PUI S 0025-7125(02)00008-1

CY United States

DT Journal; General Review

FS 008 Neurology and Neurosurgery

020 Gerontology and Geriatrics

037 Drug Literature Index

LA English

SL English

ED Entered STN: 15 Aug 2002

Last Updated on STN: 15 Aug 2002

=> d his

(FILE 'HOME' ENTERED AT 13:17:32 ON 14 JUL 2006)

FILE 'REGISTRY' ENTERED AT 13:17:47 ON 14 JUL 2006

L1 1 S ARIPIPRAZOLE/CN

L2 1 S CLOMIPRAMINE/CN

SEL L1

SEL L2

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 13:18:54 ON 14 JUL 2006

SEA (E1-E8) AND ANTIDEPRESSANT

2 FILE ADISCTI
1 FILE ADISINSIGHT
2 FILE ADISNEWS
23 FILE BIOSIS
1 FILE BIOTECHNO

15 FILE CAPLUS
 37 FILE DDFU
 43 FILE DRUGU
 260 FILE EMBASE
 1 FILE ESBIODBASE
 10 FILE IFIPAT
 3 FILE IPA
 1 FILE JICST-EPLUS
 1 FILE LIFESCI
 8 FILE MEDLINE
 6 FILE NLDB
 7 FILE PASCAL
 4 FILE PHARMAML
 7 FILE PHIN
 9 FILE SCISEARCH
 17 FILE TOXCENTER
 59 FILE USPATFULL
 3 FILE USPAT2
 1 FILE CABA
 15 FILE PROMT
 37 FILE WPIDS
 1 FILE WPIFV
 37 FILE WPINDEX
 5 FILE EPFULL
 1 FILE FRFULL
 92 FILE PCTFULL

L3 QUE ((ABILIFY/BI OR ABILITAT/BI OR ARIPIRAZOLE/BI OR "OPC 1459

FILE 'BIOSIS, DRUGU, EMBASE, USPATFULL, PCTFULL' ENTERED AT 13:24:57 ON
14 JUL 2006

L4 181 S (E1-E8) AND ((SSRI) OR (SEROTONIN(W)REUPTAKE(W)INHIBITOR))
 L5 175 DUP REM L4 (6 DUPLICATES REMOVED)
 L6 2 S L5 NOT PY>2002

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB,
 DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODBASE,
 IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI,
 MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 13:28:07 ON 14 JUL
 2006

SEA (E9-E15) AND (ATYPICAL(W)ANTIPSYCHOTIC)

14 FILE ADISCTI
 1 FILE ADISINSIGHT
 4 FILE BIOSIS
 6 FILE CAPLUS
 4 FILE DDFU
 5 FILE DRUGU
 144 FILE EMBASE
 2 FILE ESBIODBASE
 3 FILE IFIPAT
 1 FILE IPA
 2 FILE JICST-EPLUS
 4 FILE MEDLINE
 1 FILE NLDB
 3 FILE PASCAL
 6 FILE SCISEARCH
 8 FILE TOXCENTER
 36 FILE USPATFULL
 3 FILE USPAT2
 2 FILE WPIDS
 2 FILE WPINDEX
 1 FILE EPFULL
 19 FILE PCTFULL

L7 QUE ((CHLORIMIPRAMINE/BI OR CLOMIPRAMINE/BI OR "G 34586"/BI OR

FILE 'EMBASE, USPATFULL, PCTFULL' ENTERED AT 13:32:02 ON 14 JUL 2006
L8 199 S (E9-E15) AND (ATYPICAL(W) ANTIPSYCHOTIC)
L9 41 S L8 NOT PY>2002
L10 40 DUP REM L9 (1 DUPLICATE REMOVED)
L11 21 S L10 AND (DEPRESSION OR SMOKING)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 13:36:12 ON 14 JUL 2006

SEA SMOKING AND (ATYPICAL(W) ANTIPSYCHOTIC) AND (ANTIDEPRESSANT)

2 FILE ADISCTI
1 FILE ADISINSIGHT
3 FILE BIOSIS
1 FILE CAPLUS
2 FILE DRUGU
25 FILE EMBASE
2 FILE IFIPAT
1 FILE PASCAL
1 FILE PHIN
35 FILE USPATFULL
11 FILE USPAT2
5 FILE PROMT
1 FILE PROUSDDR
1 FILE WPIDS
1 FILE WPINDEX
1 FILE EPFULL
21 FILE PCTFULL

L12 QUE SMOKING AND (ATYPICAL(W) ANTIPSYCHOTIC) AND (ANTIDEPRESSANT

FILE 'EMBASE, USPATFULL, PCTFULL' ENTERED AT 13:39:07 ON 14 JUL 2006
L13 55 S SMOKING AND (ATYPICAL(W) ANTIPSYCHOTIC) AND (SSRI OR (SEROTONI
L14 3 S L13 NOT PY>2002
L15 3 DUP REM L14 (0 DUPLICATES REMOVED)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.81	85.63

STN INTERNATIONAL LOGOFF AT 13:41:12 ON 14 JUL 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 07 Coverage of Research Disclosure reinstated in DWPI
NEWS 14 JUL 11 CHEMSAFE reloaded and enhanced

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:49:29 ON 14 JUL 2006

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:49:38 ON 14 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2006 HIGHEST RN 892505-73-6
DICTIONARY FILE UPDATES: 13 JUL 2006 HIGHEST RN 892505-73-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s aripiprazole/cn
L1 1 ARIPIPRAZOLE/CN

=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.20	5.41

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:49:57 ON 14 JUL 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> sel L1
THIS COMMAND IS NOT AVAILABLE IN STNINDEX
Some commands are not allowed after the INDEX command. Enter HELP COMMANDS at an arrow prompt (=>) for a list of commands that may be used in STNINDEX.

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.61	6.02

FILE 'REGISTRY' ENTERED AT 14:50:04 ON 14 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2006 HIGHEST RN 892505-73-6
DICTIONARY FILE UPDATES: 13 JUL 2006 HIGHEST RN 892505-73-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> sel L1

E1 THROUGH E8 ASSIGNED

=> index bioscience patents

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.77	6.79

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:50:11 ON 14 JUL 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s (E1-E8) and antidepressant

2 FILE ADISCTI

1 FILE ADISINSIGHT

2 FILE ADISNEWS

23 FILE BIOSIS

1 FILE BIOTECHNO

13 FILES SEARCHED...

1 FILE CABA

15 FILE CAPLUS

37 FILE DDFU

43 FILE DRUGU

260 FILE EMBASE

29 FILES SEARCHED...

1 FILE ESBIODASE

30 FILES SEARCHED...

10 FILE IFIPAT

1 FILE JICST-EPLUS

1 FILE LIFESCI

8 FILE MEDLINE

7 FILE PASCAL

48 FILES SEARCHED...

4 FILE PHARMAML

7 FILE PHIN

15 FILE PROMT

9 FILE SCISEARCH

17 FILE TOXCENTER

59 FILE USPATFULL

3 FILE USPAT2

62 FILES SEARCHED...

37 FILE WPIDS

66 FILES SEARCHED...

1 FILE WPIFV

37 FILE WPINDEX

68 FILES SEARCHED...
5 FILE EPFULL
1 FILE FRFULL
75 FILES SEARCHED...
85 FILES SEARCHED...
92 FILE PCTFULL

29 FILES HAVE ONE OR MORE ANSWERS, 92 FILES SEARCHED IN STNINDEX

L2 QUE ((ABILIFY/BI OR ABILITAT/BI OR ARIPIRAZOLE/BI OR "OPC 14597"/BI OR "OPC 31"/BI OR 129722-12-9/BI OR 156680-99-8/BI OR "7-(4-(4-(2,3-DICHLOROPHENYL)-1-PIPERAZINYL)BUTOXY)-3,4-DIHYDROCARBOSTYRIL"/BI)) AND ANTIDEPRESSANT

=> file biosis drugu embase uspatfull pctfull
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
4.88	11.67

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 14:55:09 ON 14 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'DRUGU' ENTERED AT 14:55:09 ON 14 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 14:55:09 ON 14 JUL 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 14:55:09 ON 14 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 14:55:09 ON 14 JUL 2006
COPYRIGHT (C) 2006 Univentio

=> s (E1-E8) and antidepressant

L3 477 ((ABILIFY/BI OR ABILITAT/BI OR ARIPIRAZOLE/BI OR "OPC 14597"/BI OR "OPC 31"/BI OR 129722-12-9/BI OR 156680-99-8/BI OR "7-(4-(4-(2,3-DICHLOROPHENYL)-1-PIPERAZINYL)BUTOXY)-3,4-DIHYDROCARBOSTYRIL"/BI)) AND ANTIDEPRESSANT

=> s l3 not py>2002

L4 13 L3 NOT PY>2002

=> dup rem L4

PROCESSING COMPLETED FOR L4

L5 13 DUP REM L4 (0 DUPLICATES REMOVED)

=> d l5 1-13 ti

L5 ANSWER 1 OF 13 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS
TIFR UTILISATION D'INHIBITEURS DE CYCLO-OXYGENASE-2 POUR LE TRAITEMENT DE LA SCHIZOPHRENIE, DE TROUBLES DELIRANTS, DE TROUBLES AFFECTIFS, DE L'AUTISME OU DE TICS

L5 ANSWER 2 OF 13 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN 5-HT<sb>1A</sb> RECEPTOR SUBTYPE AGONIST
TIFR AGONISTE DU SOUS-TYPE DU RECEPTEUR 5-HT<sb>1A</sb>

L5 ANSWER 3 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Psychotropic drugs and the ECG: Focus on the QTc interval.

L5 ANSWER 4 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights

reserved on STN
 TI Neuroreceptor imaging in psychiatric disorders.

L5 ANSWER 5 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI [Quetiapine: Support for the adoption of a new atypical antipsychotic and suggestions for the official guidelines at Brazilian public health services].
 QUETIAPINA: APOIO A ADOCAO E PROPOSTA DE PROTOCOLO PARA UM NOVO ANTIPSICOTICO ATIPICO NO SISTEMA UNICO DE SAUDE (SUS).

L5 ANSWER 6 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI [Antipsychotic treatment in the fiftieth year of modern psychopharmacology: An update].
 MODERN PSIKOFARMAKOLOJININ ELLINCI YILINDA KLORPROMAZINDEN GUNUMUZE ANTIPSİKOTİK TEDAVİNİN DUNU, BUGUNU.

L5 ANSWER 7 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI [New neuroleptic and antidepressant drugs: Continuous development].
 NEUE NEUROLEPTIKA UND ANTIDEPRESSIVA: DIE ENTWICKLUNG STEHT NICHT STILL.

L5 ANSWER 8 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Academy of Managed Care Pharmacy.

L5 ANSWER 9 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Psychiatry.

L5 ANSWER 10 OF 13 DRUGU COPYRIGHT 2006 THE THOMSON CORP on STN
 TI Bipolar disorder.

L5 ANSWER 11 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Drugs of psychopharmacological revolution in clinical psychiatry.

L5 ANSWER 12 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Treatment advances in bipolar disorder - Making up for lost time.

L5 ANSWER 13 OF 13 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Problematic points of psychotropic drugs.

=> s l5 nad depression

MISSING OPERATOR L5 NAD

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l5 and depression

L6 6 L5 AND DEPRESSION

=> d L6 1-6 ti

L6 ANSWER 1 OF 6 DRUGU COPYRIGHT 2006 THE THOMSON CORP on STN
 TI Bipolar disorder.

L6 ANSWER 2 OF 6 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Academy of Managed Care Pharmacy.

L6 ANSWER 3 OF 6 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Psychiatry.

L6 ANSWER 4 OF 6 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Drugs of psychopharmacological revolution in clinical psychiatry.

L6 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS
TIFR UTILISATION D'INHIBITEURS DE CYCLO-OXYGENASE-2 POUR LE TRAITEMENT DE LA SCHIZOPHRENIE, DE TROUBLES DELIRANTS, DE TROUBLES AFFECTIFS, DE L'AUTISME OU DE TICS

L6 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN 5-HT<sb>1A</sb> RECEPTOR SUBTYPE AGONIST
TIFR AGONISTE DU SOUS-TYPE DU RECEPTEUR 5-HT<sb>1A</sb>

=> s (E1-E8) and (fluoxetine or paroxetine or clomipramine or sertaline or fluvoxamine or bupropion or duloxetine)

L7 678 ((ABILIFY/BI OR ABILITAT/BI OR ARIPIRAZOLE/BI OR "OPC 14597"/BI OR "OPC 31"/BI OR 129722-12-9/BI OR 156680-99-8/BI OR "7-(4-(4-(2,3-DICHLOROPHENYL)-1-PIPERAZINYL)BUTOXY)-3,4-DIHYDROCARBOSTYRIL"/BI)) AND (FLUOXETINE OR PAROXETINE OR CLOMIPRAMINE OR SERTALINE OR FLUVOXAMINE OR BUPROPION OR DULOXETINE)

=> s l7 not py>2002

L8 21 L7 NOT PY>2002

=> dup rem L8

PROCESSING COMPLETED FOR L8

L9 20 DUP REM L8 (1 DUPLICATE REMOVED)

=> d l9 1-20 ti

L9 ANSWER 1 OF 20 USPATFULL on STN
TI System and method for targeted interventions of physician prescription practices based on deviations from expert guidelines

L9 ANSWER 2 OF 20 USPATFULL on STN
TI Active agent delivery systems and methods for protecting and administering active agents

L9 ANSWER 3 OF 20 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS
TIFR UTILISATION D'INHIBITEURS DE CYCLO-OXYGENASE-2 POUR LE TRAITEMENT DE LA SCHIZOPHRENIE, DE TROUBLES DELIRANTS, DE TROUBLES AFFECTIFS, DE L'AUTISME OU DE TICS

L9 ANSWER 4 OF 20 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN TREATMENT OF PSYCHOTIC DISORDERS COMPRISING CO-THERAPY WITH ANTICONVULSANT DERIVATIVES AND ATYPICAL ANTIPSYCHOTICS
TIFR TRAITEMENT DES TROUBLES PSYCHOTIQUES COMPORTANT UNE CO-THERAPIE AVEC DES DERIVES ANTI-CONVULSIONS ET DES ANTI-PSYCHOTIQUES ATYPIQUES

L9 ANSWER 5 OF 20 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS
TIFR DERIVES DE CYCLOPROPYLINDOLE UTILISES EN TANT QU'INHIBITEURS SELECTIFS DE RECAPTAGE DE LA SEROTONINE

L9 ANSWER 6 OF 20 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN NEW DRUG COMBINATIONS

TIFR NOUVELLES COMBINAISONS MEDICAMENTEUSES

L9 ANSWER 7 OF 20 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND
ADMINISTERING ACTIVE AGENTS

TIFR SYSTEMES DE LIBERATIONS D'AGENTS ACTIFS ET PROCEDES DE PROTECTION ET
D'ADMINISTRATION D'AGENTS ACTIFS

L9 ANSWER 8 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Therapeutic drug monitoring: Chemical-clinical correlations of atypical
antipsychotic drugs.

L9 ANSWER 9 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI New antipsychotic agents for schizophrenia: Pharmacokinetics and
metabolism update.

L9 ANSWER 10 OF 20 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN DUPLICATE 1

TI Gateways to clinical trials.

L9 ANSWER 11 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI [Report from the USA].
BERICHT AUS USA.

L9 ANSWER 12 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Gateways to clinical trials.

L9 ANSWER 13 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI [Important for atypical antipsychotic drugs: Pharmacokinetics, interaction
potential and therapeutic drug monitoring].
WICHTIG BEI ATYPISCHEN ANTIPSYCHOTIKA: PHARMAKOKINETIK,
INTERAKTIONSPOTENTIAL UND TDM.

L9 ANSWER 14 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Psychotropic drugs and the ECG: Focus on the QTc interval.

L9 ANSWER 15 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI [Quetiapine: Support for the adoption of a new atypical antipsychotic and
suggestions for the official guidelines at Brazilian public health
services].
QUETIAPINA: APOIO A ADOCAO E PROPOSTA DE PROTOCOLO PARA UM NOVO
ANTIPSICOTICO ATIPICO NO SISTEMA UNICO DE SAUDE (SUS).

L9 ANSWER 16 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Projecting future drug expenditures - 2002.

L9 ANSWER 17 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Academy of Managed Care Pharmacy.

L9 ANSWER 18 OF 20 DRUGU COPYRIGHT 2006 THE THOMSON CORP on STN

TI Bipolar disorder.

L9 ANSWER 19 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Drugs of psychopharmacological revolution in clinical psychiatry.

L9 ANSWER 20 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Problematic points of psychotropic drugs.

=> d 19 4 5 6 15

L9 ANSWER 4 OF 20 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2002087590 PCTFULL ED 20021115 EW 200245
TIEN TREATMENT OF PSYCHOTIC DISORDERS COMPRISING CO-THERAPY WITH
TIFR ANTICONVULSANT DERIVATIVES AND ATYPICAL ANTIPSYCHOTICS
TIFR TRAITEMENT DES TROUBLES PSYCHOTIQUES COMPORTANT UNE CO-THERAPIE AVEC DES
IN DERIVES ANTI-CONVULSIONS ET DES ANTI-PSYCHOTIQUES ATYPIQUES
PA FENTON, Wayne, S., 11602 Park Edge Drive, Rockville, MD 20852, US
PA ORTHO-MCNEIL PHARMACEUTICAL, INC., U.S. Route #202, Raritan, NJ
08869-0602, US [US, US]
AG JOHNSON, Philip, S., Johnson & Johnson, One Johnson & Johnson Plaza, New
Brunswick, NJ 08933, US
LAF English
LA English
DT Patent
PI WO 2002087590 A1 20021107
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-US12997 A 20020423
PRAI US 2001-60/286,765 20010426
US 2001-60/301,661 20010628
ICM A61K031-5513
ICS A61K031-519; A61K031-35; A61P025-18

L9 ANSWER 5 OF 20 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2002079152 PCTFULL ED 20021022 EW 200241
TIEN CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS
TIFR DERIVES DE CYCLOPROPYLINDOLE UTILISES EN TANT QU'INHIBITEURS SELECTIFS
DE RECAPTAGE DE LA SEROTONINE
IN MATTSON, Ronald, 65 Smithfield Avenue, Meriden, CT 06451, US [US, US];
DENHART, Derek, 188 North Whittlesey Avenue, Wallingford, CT 06492, US
[CA, US];
DESKUS, Jeffrey, 82 Stage Harbor Road, Marlborough, CT 06447, US [US,
US];
DITTA, Jonathan, 51 Russett Lane, Middletown, CT 06457, US [US, US];
MARCIN, Lawrence, 81 Peck Road, Bethany, CT 06524, US [US, US];
EPPERSON, James, 5 Arrowwood Drive, Cromwell, CT 06416, US [US, US];
CATT, John, 6633 Cheshire Drive, Newburgh, IN 47630, US [US, US];
KING, Dalton, 114 Wakefield Street, Hamden, CT 06517, US [US, US];
HIGGINS, Mendi, 8105 Town Ridge, Middletown, CT 06457, US [US, US]
PA BRISTOL-MYERS SQUIBB COMPANY, P. O. Box 4000, Lawrenceville-Princeton
Road, Princeton, NJ 08543-4000, US [US, US], for all designates States
except US;
MATTSON, Ronald, 65 Smithfield Avenue, Meriden, CT 06451, US [US, US],
for US only;
DENHART, Derek, 188 North Whittlesey Avenue, Wallingford, CT 06492, US
[CA, US], for US only;
DESKUS, Jeffrey, 82 Stage Harbor Road, Marlborough, CT 06447, US [US,
US], for US only;
DITTA, Jonathan, 51 Russett Lane, Middletown, CT 06457, US [US, US], for
US only;
MARCIN, Lawrence, 81 Peck Road, Bethany, CT 06524, US [US, US], for US

only;
 EPPERSON, James, 5 Arrowwood Drive, Cromwell, CT 06416, US [US, US], for US only;
 CATT, John, 6633 Cheshire Drive, Newburgh, IN 47630, US [US, US], for US only;
 KING, Dalton, 114 Wakefield Street, Hamden, CT 06517, US [US, US], for US only;
 HIGGINS, Mendi, 8105 Town Ridge, Middletown, CT 06457, US [US, US], for US only

AG MAKUJINA, Shah, BRISTOL-MYERS SQUIBB COMPANY, P. O. Box 4000, Lawrenceville-Princeton Road, Princeton, NJ 08543-4000, US

LAF English
 LA English
 DT Patent
 PI WO 2002079152 A1 20021010
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
 TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2002-US6627 A 20020305
 PRAI US 2001-60/279,888 20010329
 US 2001-60/293,122 20010523
 US 2001-60/327,804 20011009
 ICM C07D209-14

L9 ANSWER 6 OF 20 PCTFULL COPYRIGHT 2006 Univentio on STN
 AN 2002053140 PCTFULL ED 20020723 EW 200228
 TIEN NEW DRUG COMBINATIONS
 TIFR NOUVELLES COMBINAISONS MEDICAMENTEUSES
 IN WONG, Erik, Ho, Fong, 7352 Hampstead Lane, Portage, MI 49024, US [US, US];
 GALLEN, Christopher, C., 8 Overbrook Parkway, Wynnewood, PA 19096, US [US, US];
 SVENSSON, Torgny, Ringvaegen 9, S-181 33 Lidingoe, SE [SE, SE]
 PA PHARMACIA & UPJOHN COMPANY, 301 Henrietta Street, Kalamazoo, MI 49001, US [US, US], for all designates States except US;
 PHARMACIA AB, Lindhagensgatan 133, S-0112 87 Stockholm, SE [SE, SE], for all designates States except US;
 WONG, Erik, Ho, Fong, 7352 Hampstead Lane, Portage, MI 49024, US [US, US], for US only;
 GALLEN, Christopher, C., 8 Overbrook Parkway, Wynnewood, PA 19096, US [US, US], for US only;
 SVENSSON, Torgny, Ringvaegen 9, S-181 33 Lidingoe, SE [SE, SE], for US only

AG NESBITT, Stephen, L., Pharmacia & Upjohn Company, Global Intellectual Property, 301 Henrietta Street, Kalamazoo, MI 49001, US

LAF English
 LA English
 DT Patent
 PI WO 2002053140 A2 20020711
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
 TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2001-US45871 A 20011227

PRAI US 2001-60/259,286 20010102
ICM A61K031-00

L9 ANSWER 15 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2005241952 EMBASE
TI [Quetiapine: Support for the adoption of a new atypical antipsychotic and suggestions for the official guidelines at Brazilian public health services].
QUETIAPINA: APOIO A ADOCAO E PROPOSTA DE PROTOCOLO PARA UM NOVO ANTIPSICOTICO ATIPICO NO SISTEMA UNICO DE SAUDE (SUS).
AU Frota L.H.; Brasil M.A.A.; Bueno J.R.; Da Silva Filho J.F.
CS Prof. L.H. Frota, R. Marques de Olinda 10/1004, CEP 22251-040 - Rio de Janeiro-RJ. leopoldo.frota@uol.com.br
SO Jornal Brasileiro de Psiquiatria, (2002) Vol. 51, No. 5, pp. 299-312. .
Refs: 62
ISSN: 0047-2085 CODEN: JBPSAX
CY Brazil
DT Journal; General Review
FS 030 Pharmacology
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles
LA Portuguese
SL English; Portuguese
ED Entered STN: 16 Jun 2005
Last Updated on STN: 16 Jun 2005

=> s (E1-E8)

L10 2388 ((ABILIFY/BI OR ABILITAT/BI OR ARIPIPRAZOLE/BI OR "OPC 14597"/BI OR "OPC 31"/BI OR 129722-12-9/BI OR 156680-99-8/BI OR "7-(4-(4-(2,3-DICHLOROPHENYL)-1-PIPERAZINYL)BUTOXY)-3,4-DIHYDROCARBOSTYRIL"/BI))

=> s l10 not py>2000

L11 136 L10 NOT PY>2000

=> s l11 and antipsychotic

L12 95 L11 AND ANTIPSYCHOTIC

=> s l12 nad dopamine

MISSING OPERATOR L12 NAD

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l12 and dopamine

L13 80 L12 AND DOPAMINE

=> s l13 not py>1998

L14 68 L13 NOT PY>1998

=> d l14 1-20 ti

L14 ANSWER 1 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI How do antipsychotics exert their effects on dopamine receptor subtypes?.

L14 ANSWER 2 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Differential effects of D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary.

L14 ANSWER 3 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Interactions of the novel antipsychotic, Aripiprazole, at the D2 dopamine receptor.

L14 ANSWER 4 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-(4(4-phenyl-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone derivatives.

L14 ANSWER 5 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Mechanisms of action of the novel antipsychotic aripiprazole (OPC-14597) .

L14 ANSWER 6 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Striatal D-2-like dopamine receptor occupancy by atypical antipsychotics in relation to antipsychotic activity and extrapyramidal side effects.

L14 ANSWER 7 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Behavioral pharmacological assessment of the postsynaptic dopamine receptor agonistic activity of aripiprazole (OPC-14597), a novel antipsychotic drug.

L14 ANSWER 8 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Antagonistic effects of OPC-14597, a novel antipsychotic drug, on quinpirole- and (-)-sulpiride-induced changes in evoked dopamine release in rat striatal slices.

L14 ANSWER 9 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D-2 receptor following repeated treatment in the rat striatum.

L14 ANSWER 10 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI The novel antipsychotic (OPC-14597) functionally discriminates between pre- and post-synaptic D-2 dopamine receptors.

L14 ANSWER 11 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area.

L14 ANSWER 12 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Differences in the effects of chronic treatments with aripiprazole on dopamine D2 receptors between in the rat striatum and pituitary.

L14 ANSWER 13 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Behavioral pharmacological studies of OPC-14597, a novel antipsychotic drug: Comparison with OPC-4392, clozapine and haloperidol.

L14 ANSWER 14 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Effects of the novel antipsychotic agent 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland.

L14 ANSWER 15 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Partial agonistic effects of OPC-14597, a potential

antipsychotic agent, on yawning behavior in rats.

L14 ANSWER 16 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Effects of the novel antipsychotic drug OPC-14597 on the dopamine D2 receptor.

L14 ANSWER 17 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI OPC-14597: Antipsychotic, Dopamine D-2 receptor antagonist, Dopamine autoreceptor agonist.

L14 ANSWER 18 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Unusual neurochemical properties of the novel antipsychotic OPC-14597 in rat striatum.

L14 ANSWER 19 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Recent progress in development of psychotropic drugs (2) Antipsychotics.

L14 ANSWER 20 OF 68 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain.

=> s l14 and depression

L15 0 L14 AND DEPRESSION

=> s l10 and depression

L16 662 L10 AND DEPRESSION

=> s l12 and depression

L17 1 L12 AND DEPRESSION

=> d l17 ti abs bib

L17 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Single or multiple receptor targets: Which are best for antipsychotic drugs.

AN 2000:414278 BIOSIS

DN PREV200000414278

TI Single or multiple receptor targets: Which are best for antipsychotic drugs.

AU Meltzer, H. Y. [Reprint author]; Ichikawa, J. [Reprint author]; Lee, M. [Reprint author]; Kostakoglu, E. [Reprint author]

CS Psychiatric Hospital at Vanderbilt, 1601 23rd Ave South, Suite 306, Nashville, TN, 37212, USA

SO Neuropsychopharmacology, (August, 2000) Vol. 23, No. S2, pp. S73. print. Meeting Info.: Second International Congress on Hormones, Brain and Neuropsychopharmacology. Rhodes, Greece. July 15-19, 2000. CODEN: NEROEW. ISSN: 0893-133X.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 27 Sep 2000

Last Updated on STN: 8 Jan 2002

=> s l16 not py>2001

L18 6 L16 NOT PY>2001

=> d l18 1-6 ti

L18 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Single or multiple receptor targets: Which are best for antipsychotic
drugs.

L18 ANSWER 2 OF 6 DRUGU COPYRIGHT 2006 THE THOMSON CORP on STN
TI Bipolar disorder.

L18 ANSWER 3 OF 6 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN
TI Bipolar disorder.

L18 ANSWER 4 OF 6 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN
TI Drugs of psychopharmacological revolution in clinical psychiatry.

L18 ANSWER 5 OF 6 USPATFULL on STN
TI Carbostyryl derivatives

L18 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM
ALLELIC VARIATIONS IN DOPAMINERGIC GENES
TIFR METHODES DE DIAGNOSTIC DE LA MIGRAINE ACCOMPAGNEE D'AURA, DE
DEPRESSION ET D'ANGOISSE, A PARTIR DE VARIATIONS ALLELIQUES DE
GENES DOPAMINERGIQUES

=> d l18 4

L18 ANSWER 4 OF 6 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN
AN 2000362601 EMBASE
TI Drugs of psychopharmacological revolution in clinical psychiatry.
AU Lieberman J.A.; Golden R.; Stroup S.; McEvoy J.
CS Dr. J.A. Lieberman, Dept. Psychiatry Univ. N. Carolina, School of
Medicine, CB 7160, Chapel Hill, NC 27599-7160, United States.
jlieberman@css.unc.edu
SO Psychiatric Services, (2000) Vol. 51, No. 10, pp. 1254-1258. .
Refs: 30
ISSN: 1075-2730 CODEN: PSSEFQ
CY United States
DT Journal; Note
FS 030 Pharmacology
032 Psychiatry
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
ED Entered STN: 13 Nov 2000
Last Updated on STN: 13 Nov 2000

=> d his

(FILE 'HOME' ENTERED AT 14:49:29 ON 14 JUL 2006)

FILE 'REGISTRY' ENTERED AT 14:49:38 ON 14 JUL 2006

L1 1 S ARIPIRAZOLE/CN

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:49:57 ON 14 JUL 2006

FILE 'REGISTRY' ENTERED AT 14:50:04 ON 14 JUL 2006

SEL L1

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:50:11 ON 14 JUL 2006
SEA (E1-E8) AND ANTIDEPRESSANT

2 FILE ADISCTI
1 FILE ADISINSIGHT
2 FILE ADISNEWS
23 FILE BIOSIS
1 FILE BIOTECHNO
1 FILE CABA
15 FILE CAPLUS
37 FILE DDFU
43 FILE DRUGU
260 FILE EMBASE
1 FILE ESBIOBASE
10 FILE IFIPAT
1 FILE JICST-EPLUS
1 FILE LIFESCI
8 FILE MEDLINE
7 FILE PASCAL
4 FILE PHARMAML
7 FILE PHIN
15 FILE PROMT
9 FILE SCISEARCH
17 FILE TOXCENTER
59 FILE USPATFULL
3 FILE USPAT2
37 FILE WPIDS
1 FILE WPIFV
37 FILE WPINDEX
5 FILE EPFULL
1 FILE FRFULL
92 FILE PCTFULL

L2 QUE ((ABILIFY/BI OR ABILITAT/BI OR ARIPIRAZOLE/BI OR "OPC 1459

FILE 'BIOSIS, DRUGU, EMBASE, USPATFULL, PCTFULL' ENTERED AT 14:55:09 ON
14 JUL 2006

L3 477 S (E1-E8) AND ANTIDEPRESSANT
L4 13 S L3 NOT PY>2002
L5 13 DUP REM L4 (0 DUPLICATES REMOVED)
L6 6 S L5 AND DEPRESSION
L7 678 S (E1-E8) AND (FLUOXETINE OR PAROXETINE OR CLOMIPRAMINE OR SERT
L8 21 S L7 NOT PY>2002
L9 20 DUP REM L8 (1 DUPLICATE REMOVED)
L10 2388 S (E1-E8)
L11 136 S L10 NOT PY>2000
L12 95 S L11 AND ANTIPSYCHOTIC
L13 80 S L12 AND DOPAMINE
L14 68 S L13 NOT PY>1998
L15 0 S L14 AND DEPRESSION
L16 662 S L10 AND DEPRESSION
L17 1 S L12 AND DEPRESSION
L18 6 S L16 NOT PY>2001

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

36.73

48.40

STN INTERNATIONAL LOGOFF AT 15:07:02 ON 14 JUL 2006